Bixiye
2019 March Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2151 - 2160 ee natiijooyinka 3613
Bixiye
P26-19 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial & Medicare Advantage Lines of Business – Effective May 6, 2019
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Bixiye
P28-19 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Members – eviCore Healthcare Utilization Management Program
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Bixiye
P25-19 Medicare Advantage PPO Network Sharing Frequently Asked Questions
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Bixiye
P29-19 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Members – eviCore Healthcare Utilization Management Program
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Bixiye
P24-19 Blue Cross to Decommission Legacy Claims System
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2019
Bixiye
QP20-19 Pharmacy Benefit Exclusion for Ultomiris (ravulizumab-cwvz) IV Injection
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP22-19 Pharmacy Benefit Update - New Drug-Related Step Therapy Criteria: Methotrexate Injectable
Taariikhda uu dhaqangalayo Barnaamijka: 27, Feb 2019
Bixiye
QP18-19 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Sucralfate Suspension
Taariikhda uu dhaqangalayo Barnaamijka: 27, Feb 2019
Bixiye
QP16-19 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Orilissa (elagolix)
Taariikhda uu dhaqangalayo Barnaamijka: 27, Feb 2019